{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:08:35Z","timestamp":1780319315343,"version":"3.54.1"},"reference-count":68,"publisher":"Medicinska Naklada d.o.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiat Danub"],"published-print":{"date-parts":[[2026,1,12]]},"DOI":"10.24869\/psyd.2025.419","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:30:26Z","timestamp":1768210226000},"page":"419-429","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic changes associated with antidepressants: Understanding the risks to achieve more than a pyrrhic victory"],"prefix":"10.24869","volume":"37","author":[{"name":"Ege University School of Medicine, Izmir, Turkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Selcuk Ozkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Psychiatry and Psychotherapy, University Hospital Schleswig-Holstein, Lubeck, Germany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokcen","family":"Unal Kocabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, Ege University School of Medicine, Izmir, Turkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"Isman Haznedaroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Psychiatry, Ege University School of Medicine, Izmir, Turkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6768","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Abrahamian, H., Hofmann, N., Kinzl, N., & Toplak, N. (2012). Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus study group). Neuropsychiatric Disease and Treatment, 355. https:\/\/doi.org\/10.2147\/ndt.s33679","DOI":"10.2147\/NDT.S33679"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Al-Khatib, Y., Akhtar, M. A., Kanawati, M. A., Mucheke, R., Mahfouz, M., & Al-Nufoury, M. (2022). Depression and Metabolic Syndrome: A Narrative review. Cureus. https:\/\/doi.org\/10.7759\/cureus.22153","DOI":"10.7759\/cureus.22153"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Annam, J., Galfalvy, H. C., Keilp, J. G., Simpson, N., Huang, Y., Nandakumar, R., Byrnes, A., Nitahara, K., Hall, A., Stanley, B., Mann, J. J., & Sublette, M. E. (2023). Plasma cytokine and growth factor response to acute psychosocial stress in major depressive disorder. Journal of Psychiatric Research, 169, 224-230. https:\/\/doi.org\/10.1016\/j.jpsychires.2023.11.029","DOI":"10.1016\/j.jpsychires.2023.11.029"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Ananloo, E. S., Ghaeli, P., Kamkar, M., & Sadeghi, M. (2013). Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression. DARU Journal of Pharmaceutical Sciences, 21(1). https:\/\/doi.org\/10.1186\/2008-2231-21-4","DOI":"10.1186\/2008-2231-21-4"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Bekka, E., & Eyer, F. (2022). Dose-related hypoglycemia in venlafaxine poisoning: a retrospective cohort study. Clinical Toxicology, 60(12), 1336-1344. https:\/\/doi.org\/10.1080\/15563650.2022.2138762","DOI":"10.1080\/15563650.2022.2138762"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. B\u00e9\u0131\u0308que, J., Lavoie, N., De Montigny, C., & Debonnel, G. (1998). Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. European Journal of Pharmacology, 349(1), 129-132. https:\/\/doi.org\/10.1016\/s0014-2999(98)00241-6","DOI":"10.1016\/S0014-2999(98)00241-6"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Bozkurt, H., & \u015eahin, S. (2016). Weight Loss Associated with Reboxetine Use in Adolescents. Journal of Child and Adolescent Psychopharmacology, 26(1), 82-83. https:\/\/doi.org\/10.1089\/cap.2015.0199","DOI":"10.1089\/cap.2015.0199"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Cashman, J. R., & Ghirmai, S. (2009). Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorganic & Medicinal Chemistry, 17(19), 6890-6897. https:\/\/doi.org\/10.1016\/j.bmc.2009.08.025","DOI":"10.1016\/j.bmc.2009.08.025"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Calegari, L., Gorenstein, C., Gentil, V., Planeta, C. S., & NunesDe-Souza, R. L. (2007). Effect of Chronic Treatment with Clomipramine on Food Intake, Macronutrient Selection and Body Weight Gain in Rats. Biological and Pharmaceutical Bulletin, 30(8), 1541-1546. https:\/\/doi.org\/10.1248\/bpb.30.1541","DOI":"10.1248\/bpb.30.1541"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Cao, T. X. D., Filliter, C., Montastruc, F., Yu, O. H. Y., Fergusson, E., Rej, S., \u2026 Renoux, C. (2022). Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths. Journal of Affective Disorders, 318, 231-237. doi:10.1016\/j.jad.2022.08.094","DOI":"10.1016\/j.jad.2022.08.094"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Carp\u00e9n\u00e9, C., Mercader, J., Gonidec, S. L., Schaak, S., Mialet-Perez, J., Zakaroff-Girard, A., & Galitzky, J. (2018). Body fat reduction without cardiovascular changes in mice after oral treatment with the MAO inhibitor phenelzine. British Journal of Pharmacology, 175(12), 2428-2440. https:\/\/doi.org\/10.1111\/bph.14211","DOI":"10.1111\/bph.14211"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Carp\u00e9n\u00e9, C., Gr\u00e8s, S., & Rascalou, S. (2012). The amine oxidase inhibitor phenelzine limits lipogenesis in adipocytes without inhibiting insulin action on glucose uptake. Journal of Neural Transmission, 120(6), 997-1003. https:\/\/doi.org\/10.1007\/s00702-012-0951-3","DOI":"10.1007\/s00702-012-0951-3"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Chittaranjan, A., Chethan, K. B., & Sandarsh, S. (2013). Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure. International Clinical Psychopharmacology, 28(3), 145-155. https:\/\/doi.org\/10.1097\/yic.0b013e32835d735d","DOI":"10.1097\/YIC.0b013e32835d735d"},{"key":"ref13","unstructured":"14. Colotto, M., Vinci, F., Vo Hong, N., Raimo, O., Castello, A., Carnovale, A., \u2026 & Coletta, P. (2012). [Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art]. La Clinica terapeutica, 163(1), e41-5."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Dadashova, R., & Silverstone, P. H. (2012). Off-label use of atomoxetine in adults: is it safe? Mental Illness, 4(2), 96-101. https:\/\/doi.org\/10.4081\/mi.2012.e19","DOI":"10.4081\/mi.2012.e19"},{"key":"ref15","unstructured":"16. Dean, L. (2020, June 29). Atomoxetine therapy and CYP2D6 genotype. Medical Genetics Summaries - NCBI Bookshelf. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK315951\/"},{"key":"ref16","unstructured":"17. De Zwaan, M., & Nutzinger, D. O. (1996). Effect of fluvoxamine on total serum cholesterol levels during weight reduction. The Journal of Clinical Psychiatry, 57(8), 346-348."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. De Diego-Adeli\u00f1o, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., et al. (2021). Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opinion on Drug Safety, 21(5), 673-690. https:\/\/doi.org\/10.1080\/14740338.2022.2019705","DOI":"10.1080\/14740338.2022.2019705"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Drieling, T., Biedermann, N.C., Sch\u00e4rer, L.O., Strobl, N., & Langosch, J.M. (2007). [Psychotropic drug-induced change of weight: a review]. Fortschritte der Neurologie-Psychiatrie, 75(2), 65-80. https:\/\/doi.org\/10.1055\/s-2005-919109","DOI":"10.1055\/s-2005-919109"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Eker, O. O., Ozsoy, S., Eker, B., & Dogan, H. (2016). Metabolic effects of antidepressant treatment. N\u00f6ro Psikiyatri Ar\u015fivi, 54(1), 49-56. https:\/\/doi.org\/10.5152\/npa.2016.12373","DOI":"10.5152\/npa.2016.12373"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Fiedorowicz, J. G., & Swartz, K. L. (2004). The role of monoamine oxidase inhibitors in current psychiatric practice. Journal of Psychiatric Practice, 10(4), 239-248. https:\/\/doi.org\/10.1097\/00131746-200407000-00005","DOI":"10.1097\/00131746-200407000-00005"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Flechtner-Mors, M., Jenkinson, C., Alt, A., Adler, G., & Ditschuneit, H. (2007). Metabolism in adipose tissue in response to citalopram and trimipramine treatment - An in situ microdialysis study. Journal of Psychiatric Research, 42(7), 578-586. https:\/\/doi.org\/10.1016\/j.jpsychires.2007.06.003","DOI":"10.1016\/j.jpsychires.2007.06.003"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Gadde, K. M., Zhang, W., & Foust, M. S. (2006). Bupropion treatment of Olanzapine-Associated weight gain. Journal of Clinical Psychopharmacology, 26(4), 409-413. https:\/\/doi.org\/10.1097\/01.jcp.0000227354.54074.5d","DOI":"10.1097\/01.jcp.0000227354.54074.5d"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Harris, B., Young, J., & Hughes, B. (1986). Comparative effects of seven antidepressant regimes on appetite, weight and carbohydrate preference. The British Journal of Psychiatry, 148(5), 590-592. https:\/\/doi.org\/10.1192\/bjp.148.5.590","DOI":"10.1192\/bjp.148.5.590"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Hu, Y., Wang, Y., Chen, C., Yang, W., Zhu, W., Wang, Y., & Liu, P. (2021). A randomized, placebo-controlled, double-blind study on the effects of SZL on patients with mild to moderate depressive disorder with comparison to fluoxetine. Journal of Ethnopharmacology, 281, 114549. https:\/\/doi.org\/10.1016\/j.jep.2021.114549","DOI":"10.1016\/j.jep.2021.114549"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Hyman Rapaport M. (2007). Translating the evidence on atypical depression into clinical practice. The Journal of Clinical Psychiatry, 68 Suppl 3, 31-36.","DOI":"10.4088\/JCP.0407e11"},{"key":"ref26","unstructured":"27. Kozumplik, O., & Uzun, S. (2011). Metabolic syndrome in patients with depressive disorder-features of comorbidity. Psychiatria Danubina, 23(1), 84-88."},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Le Melledo, J., Mailo, K., Lara, N., Abadia, M., Gil, L., Van Ameringen, M., Baker, G., & Perez-Parada, J. (2008). Paroxetine-induced increase in LDL cholesterol levels. Journal of Psychopharmacology, 23(7), 826-830. https:\/\/doi.org\/10.1177\/0269881108094320","DOI":"10.1177\/0269881108094320"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Lin, H., Simonavice, C. A., Lu, C., Lin, W., Wu, P., Chou, C., Liao, C., & Lane, H. (2017). Severe hypertriglyceridemia secondary to venlafaxine use in an older adult on dialysis -case report. BMC Health Services Research, 17(1). https:\/\/doi.org\/10.1186\/s12913-017-2195-2","DOI":"10.1186\/s12913-017-2195-2"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Lu, M., Lane, H., Lin, S., Chen, K., & Chang, W. (2004). Adjunctive fluvoxamine inhibits Clozapine-Related weight gain and metabolic disturbances. The Journal of Clinical Psychiatry, 65(6), 766-771. https:\/\/doi.org\/10.4088\/jcp.v65n0607","DOI":"10.4088\/JCP.v65n0607"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Madison, B. B. (2016). Srebp2: A master regulator of sterol and fatty acid synthesis. Journal of Lipid Research, 57(3), 333-335. https:\/\/doi.org\/10.1194\/jlr.c066712","DOI":"10.1194\/jlr.C066712"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Maina, G., Albert, U., Salvi, V., & Bogetto, F. (2004). Weight Gain during Long-Term Treatment of Obsessive-Compulsive Disorder. The Journal of Clinical Psychiatry, 65(10), 1365-1371. https:\/\/doi.org\/10.4088\/jcp.v65n1011","DOI":"10.4088\/JCP.v65n1011"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., & Kennedy, S. H. (2006). The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opinion on Drug Safety, 5(4), 523-537. https:\/\/doi.org\/10.1517\/14740338.5.4.523","DOI":"10.1517\/14740338.5.4.523"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Mercader, J., Sabater, A. G., Gonidec, S. L., Decaunes, P., Chaplin, A., G\u00f3mez-Zorita, S., Milagro, F. I., & Carp\u00e9n\u00e9, C. (2019). Oral phenelzine treatment mitigates metabolic disturbances in mice fed a High-Fat diet. Journal of Pharmacology and Experimental Therapeutics, 371(2), 555-566. https:\/\/doi.org\/10.1124\/jpet.119.259895","DOI":"10.1124\/jpet.119.259895"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Meshkat, S., F Duffy, S., K Tassone, V., Lin, Q., Ym Pang, H., Jung, H., Lou, W., & Bhat, V. (2025). Increased odds of metabolic syndrome among adults with depressive symptoms or antidepressant use. Translational Psychiatry, 15(1), 68. https:\/\/doi.org\/10.1038\/s41398-025-03289-4","DOI":"10.1038\/s41398-025-03289-4"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Morriss, R., Tyrer, F., Zaccardi, F., & Khunti, K. (2021). Safety of antidepressants in a primary care cohort of adults with obesity and depression. PLoS ONE, 16(1), e0245722. https:\/\/doi.org\/10.1371\/journal.pone.0245722","DOI":"10.1371\/journal.pone.0245722"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Nagy, C. T., Koncsos, G., Varga, Z. V., Baranyai, T., Tuza, S., Kassai, F., Ernyey, A. J., Gyerty\u00e1n, I., et al. (2018). Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats. British Journal of Pharmacology, 175(18), 3713-3726. https:\/\/doi.org\/10.1111\/bph.14437","DOI":"10.1111\/bph.14437"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Narita, K., Murata, T., Takahashi, T., Kosaka, H., Omata, N., & Wada, Y. (2006). Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(6), 1159-1162. https:\/\/doi.org\/10.1016\/j.pnpbp.2006.03.030","DOI":"10.1016\/j.pnpbp.2006.03.030"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Oakes, T. M., Katona, C., Liu, P., Robinson, M., Raskin, J., & Greist, J. H. (2012). Safety and tolerability of duloxetine in elderly patients with major depressive disorder. International Clinical Psychopharmacology, 28(1), 1-11. https:\/\/doi.org\/10.1097\/yic.0b013e32835b09cd","DOI":"10.1097\/YIC.0b013e32835b09cd"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. O'Connor, C. M., Jiang, W., Kuchibhatla, M., Silva, S. G., Cuffe, M. S., Callwood, D. D., et al. (2010). Safety and efficacy of sertraline for depression in patients with heart failure. Journal of the American College of Cardiology, 56(9), 692-699. https:\/\/doi.org\/10.1016\/j.jacc.2010.03.068","DOI":"10.1016\/j.jacc.2010.03.068"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. Paslakis, G., Gilles, M., Lederbogen, F., Schilling, C., Scharnholz, B., & Deuschle, M. (2010). The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients. European Archives of Psychiatry and Clinical Neuroscience, 261(3), 173-177. https:\/\/doi.org\/10.1007\/s00406-010-0164-4","DOI":"10.1007\/s00406-010-0164-4"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016). Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Therapeutic Advances in Psychopharmacology, 6(2), 99-144. https:\/\/doi.org\/10.1177\/2045125316629071","DOI":"10.1177\/2045125316629071"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43. Pinar, M., Gulsun, M., Tasci, I., Erdil, A., Bolu, E., Acikel, C., & Doruk, A. (2007). Maprotiline induced weight gain in depressive disorder: Changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32(1), 135-139. https:\/\/doi.org\/10.1016\/j.pnpbp.2007.07.028","DOI":"10.1016\/j.pnpbp.2007.07.028"},{"key":"ref43","unstructured":"44. Pollock, B. G., Perel, J. M., Paradis, C. F., Fasiczka, A. L., & Reynolds, C. F., 3rd (1994). Metabolic and physiologic consequences of nortriptyline treatment in the elderly. Psychopharmacology Bulletin, 30(2), 145-150."},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45. Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Faragian, S., Maayan, R., & Gil-Ad, I. (2007). Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology, 192(3), 441-448. https:\/\/doi.org\/10.1007\/s00213-007-0731-1","DOI":"10.1007\/s00213-007-0731-1"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46. Raeder, M. B., Bjelland, I., Vollset, S. E., & Steen, V. M. (2006). Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors. The Journal of Clinical Psychiatry, 67(12), 1974-1982. https:\/\/doi.org\/10.4088\/jcp.v67n1219","DOI":"10.4088\/JCP.v67n1219"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47. Rami, M., Guillamat-Prats, R., Rinne, P., Salvermoser, M., Ring, L., Bianchini, M., et al. (2018). Chronic intake of the selective serotonin reuptake inhibitor fluoxetine enhances atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology, 38(5), 1007-1019. https:\/\/doi.org\/10.1161\/atvbaha.117.310536","DOI":"10.1161\/ATVBAHA.117.310536"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48. Ricardo-Silgado, M. L., Singh, S., Cifuentes, L., Decker, P. A., Gonzalez-Izundegui, D., Moyer, A. M., Hurtado, M. D., Camilleri, M., Bielinski, S. J., & Acosta, A. (2022). Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. BMC Medicine, 20(1). https:\/\/doi.org\/10.1186\/s12916-022-02433-x","DOI":"10.1186\/s12916-022-02433-x"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49. Richards-Belle, A., Austin-Zimmerman, I., Wang, B., Zartaloudi, E., Cotic, M., et al. (2023). Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19\/CYP2D6 genes play a role? A UK population-based study. Journal of Psychopharmacology, 37(4), 396-407. https:\/\/doi.org\/10.1177\/02698811231152748","DOI":"10.1177\/02698811231152748"},{"key":"ref49","unstructured":"50. Scheen, A. (2023). [Obesity, type 2 diabetes and depression : which metabolic impact of antidepressants ?]. Revue medicale de Liege, 78(9), 516-22."},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51. Shen, Y., Brown, C. E., Li, X., Zhang, P., McGee, S. R., Spina, S. C., Loret de Mola, J. R., Fiddler, J. L., Wu, H., & Liu, Q. (2025). Selective serotonin reuptake inhibitors induce cardiac toxicity through dysfunction of mitochondria and sarcomeres. Communications Biology, 8(1), 736. https:\/\/doi.org\/10.1038\/s42003-025-08168-8","DOI":"10.1038\/s42003-025-08168-8"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52. Skinner, E., Watt, C., Reid, I., Besson, J., & Ashcroft, G. (1989). The effect of clomipramine treatment on plasma lipoproteins and high density lipoprotein subfractions in healthy subjects. Clinica Chimica Acta, 184(2), 147-154. https:\/\/doi.org\/10.1016\/0009-8981(89)90284-2","DOI":"10.1016\/0009-8981(89)90284-2"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53. Strawn, J. R., Mills, J. A., Poweleit, E. A., Ramsey, L. B., & Croarkin, P. E. (2023). Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 43(7), 675-690. https:\/\/doi.org\/10.1002\/phar.2767","DOI":"10.1002\/phar.2767"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54. Stultz, D. J., Stanley, N., Gills, T., Osburn, S., Burns, T., Moomaw, S., Pawlowska-Wajswol, S., & Walton, R. (2020). Three Months of Treatment With Esketamine: Effects on Depression, Insomnia, and Weight. The Primary Care Companion for CNS Disorders, 22(4), 19l02555. https:\/\/doi.org\/10.4088\/PCC.19l02555","DOI":"10.4088\/PCC.19l02555"},{"key":"ref54","unstructured":"55. Svacina S. (2005). Our experience with antidepressant treatment in the obese and type 2 diabetics. Prague Medical Report, 106(3), 291-296."},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"56. Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology, 340(2-3), 249-258. https:\/\/doi.org\/10.1016\/s0014-2999(97)01393-9","DOI":"10.1016\/S0014-2999(97)01393-9"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"57. Tian, Z., Wang, X., Han, T., & Sun, C. (2023). Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice. International Immunopharmacology, 117, 109901. https:\/\/doi.org\/10.1016\/j.intimp.2023.109901","DOI":"10.1016\/j.intimp.2023.109901"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"58. Tovilla-Z\u00e1rate, C. A., P\u00e9rez-Mandujano, A., Ram\u00edrez-Gonz\u00e1lez, I. R., Fresan, A., Suarez-Mendez, S., et al. (2019). Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes. Annals of Translational Medicine, 7(22), 656. https:\/\/doi.org\/10.21037\/atm.2019.10.56","DOI":"10.21037\/atm.2019.10.56"},{"key":"ref58","unstructured":"59. Trindade, E., Menon, D., Topfer, L. A., & Coloma, C. (1998). Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 159(10), 1245-1252."},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"60. Ungvari, Z., Tarantini, S., Yabluchanskiy, A., & Csiszar, A. (2019). Potential adverse cardiovascular effects of treatment with fluoxetine and other selective serotonin reuptake inhibitors (SSRIs) in patients with geriatric depression: implications for atherogenesis and cerebromicrovascular dysregulation. Frontiers in Genetics, 10. https:\/\/doi.org\/10.3389\/fgene.2019.00898","DOI":"10.3389\/fgene.2019.00898"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"61. Unis, A., Abdelbary, A., & Hamza, M. (2013). Comparison of the effects of escitalopram and atorvastatin on diet-induced atherosclerosis in rats. Canadian Journal of Physiology and Pharmacology, 92(3), 226-233. https:\/\/doi.org\/10.1139\/cjpp-2013-0168","DOI":"10.1139\/cjpp-2013-0168"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"62. Wozniak, G., Toska, A., Saridi, M., & Mouzas, O. (2011). Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Medical Science Monitor, 17(9), RA205-RA214. https:\/\/doi.org\/10.12659\/msm.881924","DOI":"10.12659\/MSM.881924"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63. Wright, M. E., & Rizzolo, D. (2017). An update on the pharmacologic management and treatment of neuropathic pain. JAAPA, 30(3), 13-17. https:\/\/doi.org\/10.1097\/01.jaa.0000512228.23432.f7","DOI":"10.1097\/01.JAA.0000512228.23432.f7"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64. Yasuda, H., Hotta, N., Kasuga, M., Kashiwagi, A., Kawamori, R., Yamada, T., Baba, Y., Alev, L., & Nakajo, K. (2015). Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study. Journal of Diabetes Investigation, 7(1), 100-108. https:\/\/doi.org\/10.1111\/jdi.12361","DOI":"10.1111\/jdi.12361"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65. Yeung, A. W. K., Georgieva, M. G., Atanasov, A. G., & Tzvetkov, N. T. (2019). Monoamine oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis. Frontiers in Molecular Neuroscience, 12. https:\/\/doi.org\/10.3389\/fnmol.2019.00143","DOI":"10.3389\/fnmol.2019.00143"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"66. Zhang, M., Huang, F., Jiang, F., Mai, M., Guo, X., Zhang, Y., Xu, Y., & Zu, H. (2022). Clinical efficacy and safety of lowdose doxepin in Chinese patients with generalized anxiety disorder: A before-after study. Medicine, 101(42), e31201. https:\/\/doi.org\/10.1097\/md.0000000000031201","DOI":"10.1097\/MD.0000000000031201"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"67. Zhao, M., You, B., Wang, X., Huang, J., Zhou, M., Shi, R., & Zhang, G. (2023). Desipramine enhances the stability of atherosclerotic plaque in rabbits monitored with molecular imaging. PLoS ONE, 18(3), e0283612. https:\/\/doi.org\/10.1371\/journal.pone.0283612","DOI":"10.1371\/journal.pone.0283612"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"68. Zheng, C., Zhu, Y., Liu, Q., Luo, T., & Xu, W. (2021). Maprotiline suppresses cholesterol biosynthesis and hepatocellular carcinoma progression through direct targeting of CRABP1. Frontiers in Pharmacology, 12. https:\/\/doi.org\/10.3389\/fphar.2021.689767","DOI":"10.3389\/fphar.2021.689767"}],"container-title":["PSYCHIATRIA DANUBINA"],"original-title":["Metabolic changes associated with antidepressants: Understanding the risks to achieve more than a pyrrhic victory"],"link":[{"URL":"https:\/\/www.psychiatria-danubina.com\/UserDocsImages\/pdf\/dnb_vol37_no4\/dnb_vol37_no4_419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:24:21Z","timestamp":1780316661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.psychiatria-danubina.com\/UserDocsImages\/pdf\/dnb_vol37_no4\/dnb_vol37_no4_419.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":68,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.24869\/psyd.2025.419","relation":{},"ISSN":["0353-5053"],"issn-type":[{"value":"0353-5053","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}